Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Monoclonal Antibodies for Cancer Immunotherapy Publisher



Zarnani AH1, 2 ; Jafari D3, 4 ; Bozorgmehr M2 ; Shabani M5 ; Barzegaryarmohammadi L5 ; Ghaemimanesh F5 ; Jedditehrani M5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pathobiology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Immunobiology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
  3. 3. Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  4. 4. Immunotherapy Research and Technology Group, Zanjan University of Medical Sciences, Zanjan, Iran
  5. 5. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Source: Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition Published:2020


Abstract

Over the past few decades, monoclonal antibodies (mAbs), as potent antitumor tools, have remarkably advanced the cancer therapy, because of their target specificity as well as little off-target effects in comparison to most small molecule drugs. The use of antibody engineering methods has made it possible for investigators to develop antibody structures with improved efficacy for application in clinical practice. The development of efficacious therapeutic mAbs entails gaining in-depth knowledge about factors including antibody structure and function, the properties of an ideal tumor antigen, the advantages of employing combinational therapies, and the limitations of antibody-based modalities. This chapter concentrates on mAbs as versatile platforms for cancer immunotherapy. © Springer Nature Switzerland AG 2015, 2021. All rights reserved.
Related Docs
View other Related Docs
1. An Overview on Display Systems (Phage, Bacterial, and Yeast Display) for Production of Anticancer Antibodies; Advantages and Disadvantages, International Journal of Biological Macromolecules (2022)
2. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
3. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
4. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)
5. Receptor Tyrosine Kinase-Like Orphan Receptor 1: A Novel Target for Cancer Immunotherapy, Expert Opinion on Therapeutic Targets (2015)
6. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)
7. Advances in Phage Display Technology for Drug Discovery, Expert Opinion on Drug Discovery (2015)
8. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (28)
Fazel Shokri (15)
Other Related Docs
9. A Concise Review on Cancer Treatment Methods and Delivery Systems, Journal of Drug Delivery Science and Technology (2019)
10. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
11. Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents, Tumor Biology (2016)
12. Targets for Improving Tumor Response to Radiotherapy, International Immunopharmacology (2019)
13. Combination Therapy of Macromolecules and Small Molecules: Approaches, Advantages, and Limitations, Nanostructures for Cancer Therapy (2017)
14. Polyclonal Antibody Against Different Extracellular Subdomains of Her2 Induces Tumor Growth Inhibition in Vitro, Iranian Journal of Immunology (2017)
15. Cancer Imaging With Radiolabeled Monoclonal Antibodies, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
16. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
17. Production of Recombinant Human Scfv Against Tetanus Toxin Heavy Chain by Phage Display Technology, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2015)
18. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
19. Personalized Medicine in Breast Cancer: Pharmacogenomics Approaches, Pharmacogenomics and Personalized Medicine (2019)
20. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)
21. Targeted Cancer Therapy Through Antibody Fragments-Decorated Nanomedicines, Journal of Controlled Release (2017)
22. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
23. Tumor Immunology, Clinical Immunology (2022)
24. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
25. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
26. Development and Clinical Application of Bispecific Antibody in the Treatment of Colorectal Cancer, Expert Review of Clinical Immunology (2020)
27. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
28. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
29. Licensed Monoclonal Antibodies and Associated Challenges, Human Antibodies (2015)
30. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
31. The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders, Biomedicine and Pharmacotherapy (2019)
32. Epitope Mapping of Human Her2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains, Asian Pacific Journal of Cancer Prevention (2017)
33. Immunopet: Antibody-Based Pet Imaging in Solid Tumors, Frontiers in Medicine (2022)
34. Fcγ1 Fragment of Igg1 As a Powerful Affinity Tag in Recombinant Fc-Fusion Proteins: Immunological, Biochemical and Therapeutic Properties, Critical Reviews in Biotechnology (2017)
35. Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review, Vaccines (2023)
36. Breast Cancer Immunotherapy: Current and Novel Approaches, International Immunopharmacology (2021)
37. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)
38. Affinity Maturation and Characterization of the Ofatumumab Monoclonal Antibody, Journal of Cellular Biochemistry (2019)
39. Adverse Events Following Administration of Anti-Ctla4 Antibody Ipilimumab, Frontiers in Oncology (2021)
40. A Novel Fc-Engineered Anti-Her2 Bispecific Antibody With Enhanced Antitumor Activity, Journal of Immunotherapy (2023)
41. Radiotherapy Combination: Insight From Tumor Immune Microenvironment (Time), Avicenna Journal of Medical Biotechnology (2023)
42. Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma, International Journal of Molecular Sciences (2020)
43. Targeting Macrophage-Mediated Tumor Cell Phagocytosis: An Overview of Phagocytosis Checkpoints Blockade, Nanomedicine Intervention, and Engineered Car-Macrophage Therapy, International Immunopharmacology (2022)
44. Design and Evaluation of Scfv-Rtx-A As a Novel Immunotoxin for Breast Cancer Treatment: An in Silico Approach, Journal of Immunoassay and Immunochemistry (2021)
45. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
46. Abscopal Effect in Radioimmunotherapy, International Immunopharmacology (2020)
47. Identification of a Novel Single Chain Fragment Variable Antibody Targeting Cd24-Expressing Cancer Cells, Immunology Letters (2017)
48. Inhibition of Tumor Growth by Mouse Ror1 Specific Antibody in a Syngeneic Mouse Tumor Model, Immunology Letters (2018)
49. Hersintuzumab: A Novel Humanized Anti-Her2 Monoclonal Antibody Induces Potent Tumor Growth Inhibition, Investigational New Drugs (2018)
50. Development of a Novel Inhibitory Chimeric Anti-Her2 Monoclonal Antibody, Iranian Journal of Immunology (2019)